BMY: Analysis & Opinions

  1. Roche, Reloaded

    May 21, 2013
    Roche has one of the best long-term growth profiles in the Big Pharma space
  2. After A Big Rally, Pfizer Might Need Some Rest

    May 21, 2013
    A big rally has brought Pfizer back to fair value.
  3. Adasuve Deal Is Very Good For Alexza, But What About Teva?

    May 09, 2013
    Teva's partnership with Alexza looks like an expensive gamble.
  4. The “Healthy” Play In Contract Research Organizations

    April 17, 2013
    The pharmaceutical industry is under pressure to do more with less. That means it will be farming out many of is ...
  5. MDCO-BMY Deal Comes into Effect - Analyst Blog

    February 11, 2013
    The Medicines Company (MDCO) recently announced that its two-year global collaboration agreement for Recothrom with ...
  6. Vical's Loss Narrower than Expected - Analyst Blog

    February 08, 2013
    Vical Inc. (VICL) suffered a net loss per share of 9 cents in the fourth quarter of 2012, narrower than the Zacks ...
  7. Generics Continue to Hurt Sanofi - Analyst Blog

    February 08, 2013
    Sanofi (SNY) reported fourth quarter 2012 business earnings of 77 cents per American Depository Share (ADS), in line ...
  8. Pipeline Setback for Idenix - Analyst Blog

    February 07, 2013
    Idenix Pharmaceuticals, Inc. (IDIX) recently announced that the company has decided to discontinue its clinical ...
  9. Brightcove Reports Mixed 4Q - Analyst Blog

    February 05, 2013
    Brightcove Inc. (BCOV) reported a loss of 13 cents in the fourth quarter of 2012, wider than the Zacks Consensus ...
  10. Alkermes Turns to Profit, Ups View - Analyst Blog

    February 01, 2013
    Alkermes plc (ALKS) reported earnings of 14 cents per share in the third quarter of fiscal 2013 (ended December 31, ...
  11. Stock Market News for January 30, 2013 - Market News

    January 30, 2013
    Better-than-expected quarterly results once again guided the S&P 500 and the Dow Jones into the green on Tuesday. ...
  12. MedTech Industry Stock Outlook - Jan 2013 - Zacks ...

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the ...
  13. MedTech Industry Stock Outlook - Jan 2013 - Industry Outlook

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the ...
  14. Cadence Forecasts Ofirmev Sales - Analyst Blog

    January 25, 2013
    Cadence Pharmaceuticals Inc. (CADX) recently announced that it expects preliminary net revenue of Ofirmev ...
  15. Label Expansion for Roche's Avastin - Analyst Blog

    January 24, 2013
    The US Food and Drug Administration (FDA) recently approved Roche's (RHHBY) Avastin (bevacizumab) in combination ...
  16. Earnings Beat at Bristol-Myers - Analyst Blog

    January 24, 2013
    Bristol-Myers Squibb Company's (BMY) fourth quarter 2012 earnings (excluding special items) of 47 cents per share ...
  17. Brackish Waters for the Market to Swim - Analyst Blog

    January 24, 2013
    We will see a very interesting interplay of competing forces in today's market action, with the Apple (AAPL) ...
  18. Ahead of Wall Street - January 24, 2013 - Ahead of Wall ...

    January 24, 2013
    Thursday, January 24, 2013 We will see a very interesting interplay of competing forces in today's market action, ...
  19. CHMP Positive on Pfizer's Bosutinib - Analyst Blog

    January 23, 2013
    Pfizer Inc. (PFE) recently received a positive opinion from the European Medicines Agency's (EMA) Committee for ...
  20. Bristol-Myers Preview: Will it Miss? - Analyst Blog

    January 21, 2013
    Bristol-Myers Squibb Company (BMY) is scheduled to release its fourth-quarter 2012 results before the opening bell ...
Marketplace
Trading Center